From early 2021 through the middle of 2025, small-cap biotech stocks significantly underperformed the broader market.
The FDA has embraced accelerated approval pathways to help biotechnology companies bring forth promising therapies to patients at a faster pace.
Intra-Cellular Therapies, a commercial-stage biotech focused on treatments for psychiatric disorders, was acquired by Johnson & Johnson, for $14.6 billion.
Read the Entire Article
A customized collection of news from foundations from around the Web.

CNote is a women-led impact investment platform that uses technology to unlock diversified and proven community investments that increase economic mobility and financial inclusion.